Allogeneic Cell Therapies Well Suited to Pharma's Biz Model, Education of Data Scientists Important: Astellas Chairman

Astellas Chairman Yoshihiko Hatanaka Astellas Pharma Chairman Yoshihiko Hatanaka explained his company’s cell therapy strategy on July 3, saying that allogeneic pluripotent stem cells (PSCs) “are well suited to the business model of the pharmaceutical industry,” because they reduce production...read more